Drugs / folic acid

Trials 9

19921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT02773147 Apr 2016 → Nov 2018 HIV infectious disease Göteborg University Unknown No outcome recorded
Phase 2 NCT00054938 Mar 2003 → Dec 2005 systemic lupus erythematosus Brigham and Women's Hospital Completed No outcome recorded
Phase 2/31 trial · 1 missed
Phase 2/3 NCT00272324 Feb 1992 → Jan 2007 colon adenoma, colorectal cancer, polyp of colon Dartmouth-Hitchcock Medical Center Completed Missed primary
Phase 31 trial · 1 missed
Phase 3 NCT00056225 Jan 2003 → Jun 2007 Alzheimer disease National Institute on Aging (NIA) Completed Missed primary
Phase 44 trials · 1 missed
Phase 4 NCT07592897 Jun → Nov 2026 expected — University of Sao Paulo Not yet recruiting No outcome recorded
Phase 4 NCT07523646 May 2026 → Apr 2028 expected anemia, infective endocarditis Rigshospitalet, Denmark Recruiting No outcome recorded
Phase 4 NCT00226356 Dec 2004 → Jun 2007 major depressive disorder Cambridge Health Alliance Completed No outcome recorded
Phase 4 NCT00249288 Dec 2003 → Jun 2008 schizophrenia Massachusetts General Hospital Completed Missed primary
Phase not applicable1 trial
— NCT03073590 Jan 2016 → Jun 2017 anemia International Centre for Diarrhoeal Disease Research, Bangladesh Completed No outcome recorded
Comparator or background therapy9 trials
Phase 2 NCT00227019 Background Mar 2006 → Nov 2010 metastatic neoplasm, non-small cell lung carcinoma Heather Wakelee Completed No outcome recorded
Phase 2 NCT00243412 Background Aug 2005 → Feb 2009 rheumatoid arthritis Genentech, Inc. Completed No outcome recorded
Phase 3 NCT02576067 Background Dec 2015 → Mar 2019 atherosclerotic cardiovascular disease, vasculitis Icahn School of Medicine at Mount Sinai Completed No outcome recorded
Phase 3 NCT00299104 Background Jan 2006 → Sep 2008 rheumatoid arthritis Genentech, Inc. Completed Met primary
Phase 3 NCT00266227 Background Jan 2006 → Oct 2007 rheumatoid arthritis Genentech, Inc. Completed No outcome recorded

Press releases naming this drug 875 releases

DateIssuerRelease
2026-10-10 Hoffmann-La Roche Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss roche.com ↗
2026-10-09 Hoffmann-La Roche FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer roche.com ↗
2026-10-01 Hoffmann-La Roche Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions roche.com ↗
2026-10-01 Hoffmann-La Roche Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine roche.com ↗
2026-09-30 Hoffmann-La Roche Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis roche.com ↗
2026-09-23 Hoffmann-La Roche Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN) roche.com ↗
2026-09-23 Hoffmann-La Roche Change in Roche’s Board of Directors roche.com ↗
2026-09-22 Hoffmann-La Roche [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity roche.com ↗
2026-09-21 Hoffmann-La Roche European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD) roche.com ↗
2026-09-18 Hoffmann-La Roche CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis roche.com ↗
2026-09-17 Hoffmann-La Roche Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases roche.com ↗
2026-09-17 Hoffmann-La Roche Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study roche.com ↗
Show all 875 releases opens the full record — a long page

Evidence & citations 37 cited values

Every value below carries the sentence it was read from. 19 sources stand behind the page.

FieldValueCited text
Known as folic acid “high-dose folate (folic acid), B6, and B12 supplementation” NCT00056225 ↗
1

“Folate (folic acid) - 400 mcg” NCT07592897 ↗

Known as Acide folique ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Acido folico ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Acidum folicum ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as B03BB01 ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Bio science ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Folacin ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Folate “the intervention will consist of the twice weekly provision of iron/folate supplements to female workers, and the enhanced BCC program, as described above.” NCT03073590 ↗
17

“Vitamin supplementation (i.e. multivitamin, vitamin B12 and/or folate) will follow Danish clinical recommendations.” NCT07523646 ↗

“Study participants will additionally receive 1 mg daily oral folate.” NCT02576067 ↗

“Folate (folic acid) - 400 mcg” NCT07592897 ↗

NCT00056225 ↗

NCT00272324 ↗

NCT05288153 ↗

NCT00299130 ↗

NCT00243412 ↗

NCT00299104 ↗

NCT02773147 ↗

Show 7 more sources

Known as Folate or folic acid “Folate or folic acid” NCT00249288 ↗
Known as FOLATE SODIUM ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Foldine ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Folettes ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Foliamin ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Folic acid component of folvron ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Folic acid component of vitaped ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Folic acid sodium salt ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Folic acid, monosodium salt ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Folicare ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Folicet ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Folipac ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Folsan ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Folvite ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Incafolic ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Lexpec ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗
Known as Millafol ChEMBL registry synonym — accepted as the source's own label CHEMBL1622 ↗